Trial NCT02034097

View at ClinicalTrials.gov 
Org. Study IDs: 112132

Last trial update was posted on 2014-05-19

MeSH Interventions

Erlotinib Hydrochloride

MeSH Conditions

Carcinoma, Non-Small-Cell Lung Lung Neoplasms

Other Conditions

Cancer

Stopping Reasons

GSK has decided to terminate the Product Development of foretinib and conclude our Development Agreement with Exelixis

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID